FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Drug Test Anal / Gene Editing and the Future of Thoroughbred Breeding and Rac...
Drug testing and analysis2026; doi: 10.1002/dta.70056

Gene Editing and the Future of Thoroughbred Breeding and Racing.

Abstract: Prohibited gene editing in horses (either in embryos or via cell culture and cloning) can result in both desired and undesired outcomes. If left undetected, changes can proliferate within the population in subsequent generations, posing a major threat to welfare and breed integrity.
© 2026 John Wiley & Sons Ltd.
Get Full Text
Publication Date: 2026-03-11 PubMed ID: 41812645DOI: 10.1002/dta.70056Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Gene editing in thoroughbred horses involves modifying their genetic material to potentially enhance desirable traits, but unauthorized use of this technology risks unintended consequences that could harm horse welfare and the integrity of the breed.

Overview of Gene Editing in Thoroughbred Horses

  • Gene editing refers to the deliberate alteration of an organism’s DNA to achieve desired traits or eliminate undesirable ones.
  • In thoroughbred horses, this technology could be applied to improve racing performance, disease resistance, or other traits valued in breeding and racing.
  • The use of gene editing can occur at different stages, including editing embryos directly or through techniques involving cell culture and cloning.

Risks and Concerns Associated with Prohibited Gene Editing

  • Prohibited gene editing suggests unauthorized or unregulated interventions that may not be subject to oversight or ethical review.
  • Such interventions can lead to both intended (desired performance or health improvements) and unintended (off-target genetic changes) outcomes.
  • Undetected genetic modifications may propagate through breeding, becoming widespread in future generations without awareness or control.
  • This proliferation could potentially compromise the welfare of horses by introducing harmful mutations or unintended health issues.
  • It also raises significant concerns about maintaining the integrity of the thoroughbred breed, which relies on documented lineage and genetic consistency.

Implications for Welfare and Breed Integrity

  • Animal welfare is at risk if gene editing results in unforeseen health problems, reduced viability, or unintended physiological effects.
  • Preserving breed integrity is critical in the thoroughbred industry, where lineage and genetic purity are fundamental to racing standards and breeding practices.
  • The unregulated spread of edited genes could erode trust in the breed registry and undermine the sport’s credibility.
  • These issues highlight the need for stringent detection methods and regulatory frameworks to monitor and control gene editing applications in horses.

Conclusion and Future Considerations

  • The potential benefits of gene editing in thoroughbred breeding must be balanced against the ethical, welfare, and integrity risks posed by unauthorized use.
  • Effective surveillance and regulatory measures should be developed to detect gene editing interventions and prevent unintentional genetic changes from spreading.
  • Stakeholders in the racing and breeding industry should engage in dialogue to establish guidelines that ensure responsible use of gene editing technologies if they are to be implemented in the future.

Cite This Article

APA
Ryder E, Given J, Hamilton N. (2026). Gene Editing and the Future of Thoroughbred Breeding and Racing. Drug Test Anal. https://doi.org/10.1002/dta.70056

Publication

Drug testing and analysis
ISSN: 1942-7611
NlmUniqueID: 101483449
Country: England
Language: English

Researcher Affiliations

Ryder, Edward
  • LGC Ltd, Fordham, UK.
Given, James
  • British Horseracing Authority, London, UK.
Hamilton, Natasha
  • Equine Genetics Research Centre, Racing Australia, Scone, New South Wales, Australia.

References

This article includes 50 references
  1. Cunningham EP, Dooley JJ, Splan RK, Bradley DG. Microsatellite Diversity, Pedigree Relatedness and the Contributions of Founder Lineages to Thoroughbred Horses. Animal Genetics 32 (2001): 360–364.
    doi: 10.1046/j.1365‐2052.2001.00785.xgoogle scholar: lookup
  2. Felkel S, Vogl C, Rigler D. The Horse Y Chromosome as an Informative Marker for Tracing Sire Lines. Scientific Reports 9 (2019): 1–12.
    doi: 10.1038/s41598‐019‐42640‐wgoogle scholar: lookup
  3. Bower MA, Campana MG, Whitten M. The Cosmopolitan Maternal Heritage of the Thoroughbred Racehorse Breed Shows a Significant Contribution From British and Irish Native Mares. Biology Letters 7 (2010): 316.
    doi: 10.1098/rsbl.2010.0800google scholar: lookup
  4. Furukawa R, Tozaki T, Mizukami K. Mutation Rate and Spectrum of Germline De Novo Mutations in a Closed Population of Thoroughbred Horses. Journal of Equine Veterinary Science 154 (2025): 105682.
    doi: 10.1016/j.jevs.2025.105682google scholar: lookup
  5. Gu J, Orr N, Park SD. A Genome Scan for Positive Selection in Thoroughbred Horses. PLoS ONE 4 (2009): e5767.
    doi: 10.1371/journal.pone.0005767google scholar: lookup
  6. The Jockey Club, accessed December 9, 2025, https://jockeyclub.com/default.asp?section=Resources&area=21.
  7. McGivney BA, Han H, Corduff LR. Genomic Inbreeding Trends, Influential Sire Lines and Selection in the Global Thoroughbred Horse Population. Scientific Reports 10 (2020): 466.
    doi: 10.1038/s41598‐019‐57389‐5google scholar: lookup
  8. Elcombe ME, Bellone RR, Magdesian KG, Finno CJ. Prevalence of the RAPGEF5 c.2624C>A and PLOD1 c.2032G>A Variants Associated With Equine Familial Isolated Hypoparathyroidism and Fragile Foal Syndrome in the US Thoroughbred Population (1988–2019). Equine Veterinary Journal 55 (2023): 666–671.
    doi: 10.1111/evj.13883google scholar: lookup
  9. Palomino Lago E, Baird A, Blott SC. A Functional Single‐Nucleotide Polymorphism Upstream of the Collagen Type III Gene Is Associated With Catastrophic Fracture Risk in Thoroughbred Horses. Animals (Basel) 14 (2023): 116.
    doi: 10.3390/ani14010116google scholar: lookup
  10. Pinzon‐Arteaga C, Snyder MD, Lazzarotto CR. Efficient Correction of a Deleterious Point Mutation in Primary Horse Fibroblasts With CRISPR‐Cas9. Scientific Reports 10 (2020): 7411.
    doi: 10.1038/s41598‐020‐62723‐3google scholar: lookup
  11. Kim DE, Lee JH, Bin Ji K. Prime Editor‐Mediated Correction of a Pathogenic Mutation in Purebred Dogs. Scientific Reports 12 (2022): 12905.
    doi: 10.1038/s41598‐022‐17200‐4google scholar: lookup
  12. Lin JC, Van AL. Electroporation‐Mediated Genome Editing of Livestock Zygotes. Frontiers in Genetics 12 (2021): 648482.
    doi: 10.3389/fgene.2021.648482google scholar: lookup
  13. Dordas‐Perpinya M, François Bruyas J, Bruyas JF. Practical Aspects of Equine Embryo Transfer. Translational. Research in Veterinary Science 2 (2019): 23–39.
    doi: 10.12775/trvs.2019.002google scholar: lookup
  14. Galli C, Lazzari G. 25th Anniversary of Cloning by Somatic‐Cell Nuclear Transfer: Current Applications of SCNT in Advanced Breeding and Genome Editing in Livestock. Reproduction 162 (2021): F23–F32.
    doi: 10.1530/rep‐21‐0006google scholar: lookup
  15. Cortez JV, Hardwicke K, Cuervo‐Arango J, Grupen CG. Cloning Horses by Somatic Cell Nuclear Transfer: Effects of Oocyte Source on Development to Foaling. Theriogenology 203 (2023): 99–108.
    doi: 10.1016/j.theriogenology.2023.03.018google scholar: lookup
  16. Navarro‐Serna S, Vilarino M, Park I, Gadea J, Ross PJ. Livestock Gene Editing by One‐Step Embryo Manipulation. Journal of Equine Veterinary Science 89 (2020): 103025.
    doi: 10.1016/j.jevs.2020.103025google scholar: lookup
  17. “UK Medicines Regulator Approves World‐First Gene‐Editing Treatment for Blood Disorders,” Imperial College Healthcare NHS Trust, accessed December 9, 2025, https://www.imperial.nhs.uk/about‐us/news/uk‐medicines‐regulator‐approves‐world‐first‐gene‐editing‐treatment‐for‐blood‐disorders.
  18. Chiesa R, Georgiadis C, Syed F. Base‐Edited CAR7 T Cells for Relapsed T‐Cell Acute Lymphoblastic Leukemia. New England Journal of Medicine 389 (2023): 899–910.
    doi: 10.1056/nejmoa2300709google scholar: lookup
  19. Amoasii L, Hildyard JCW, Li H. Gene Editing Restores Dystrophin Expression in a Canine Model of Duchenne Muscular Dystrophy. Science 362 (2018): 86–91.
    doi: 10.1126/science.aau1549google scholar: lookup
  20. Arnson B, Kang HR, Brooks ED. Genome Editing Using Staphylococcus Aureus Cas9 in a Canine Model of Glycogen Storage Disease Ia. Molecular Therapy ‐ Methods & Clinical Development 29 (2023): 108–119.
    doi: 10.1016/j.omtm.2023.03.001google scholar: lookup
  21. Jinek M, Chylinski K, Fonfara I. A Programmable Dual‐RNA‐Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science 337 (2012): 816–821.
    doi: 10.1126/science.1225829google scholar: lookup
  22. Shakweer WME, Krivoruchko AY, Dessouki SM, Khattab AA. A Review of Transgenic Animal Techniques and Their Applications. Genetic Engineering & Biotechnology Journal 21 (2023): 55.
    doi: 10.1186/s43141-023-00502-zgoogle scholar: lookup
  23. Ares E, Coe S. Genetic Technology (Precision Breeding) Bill 2022–23. .
  24. “Intentional Genomic Alterations (IGAs) in Animals,” FDA, accessed December 9, 2025, https://www.fda.gov/animal‐veterinary/biotechnology‐products‐cvm‐animals‐and‐animal‐food/intentional‐genomic‐alterations‐igas‐animals.
  25. Gelinsky E, Hilbeck A. European Court of Justice Ruling Regarding New Genetic Engineering Methods Scientifically Justified: A Commentary on the Biased Reporting About the Recent Ruling. Environmental Sciences Europe 30 (2018): 52.
    doi: 10.1186/s12302-018-0182-9google scholar: lookup
  26. “Commission Welcomes Provisional Agreement on New Genomic Techniques for Plants,” accessed December 9, 2025, https://ec.europa.eu/commission/presscorner/detail/en/ip_25_2912.
  27. International Federation of Horseracing Authorities, accessed December 10, 2025, https://www.ifhaonline.org/default.asp?section=IABRW&area=2#article6b.
  28. Moro LN, Viale DL, Bastón JI. Generation of Myostatin Edited Horse Embryos Using CRISPR/Cas9 Technology and Somatic Cell Nuclear Transfer. Scientific Reports 10 (2020): 1–10.
    doi: 10.1038/s41598-020-72040-4google scholar: lookup
  29. “World's First Genetically Edited Horses Set to Make Polo Faster,” 2024, https://www.thetimes.com/uk/science/article/worlds‐first‐genetically‐edited‐horses‐set‐to‐make‐polo‐faster‐mbwd0kpsl.
  30. Rooney MF, Hill EW, Kelly VP, Porter RK. The “Speed Gene” Effect of Myostatin Arises in Thoroughbred Horses due to a Promoter Proximal SINE Insertion. PLoS ONE 13 (2018): e0205664.
    doi: 10.1371/journal.pone.0205664google scholar: lookup
  31. Dall’Olio S, Scotti E, Fontanesi L, Tassinari M. Analysis of the 227 bp Short Interspersed Nuclear Element (SINE) Insertion of the Promoter of the Myostatin (MSTN) Gene in Different Horse Breeds. Veterinaria Italiana 50 (2014): 193–197.
    doi: 10.12834/vetit.61.178.3google scholar: lookup
  32. Petersen JL, Valberg SJ, Mickelson JR, McCue ME. Haplotype Diversity in the Equine Myostatin Gene With Focus on Variants Associated With Race Distance Propensity and Muscle Fiber Type Proportions. Animal Genetics 45 (2014): 827–835.
    doi: 10.1111/age.12205google scholar: lookup
  33. Maniego J, Giles O, Hincks P. Long‐Read Sequencing Assays Designed to Detect Potential Gene Editing Events in the Myostatin Gene Revealed Distinct Haplotype Signatures in the Thoroughbred Horse Population. Animal Genetics 54 (2023): 470–482.
    doi: 10.1111/age.13332google scholar: lookup
  34. Han H, McGivney BA, Allen L. Common Protein‐Coding Variants Influence the Racing Phenotype in Galloping Racehorse Breeds. Communications Biology 5 (2022): 1–16.
    doi: 10.1038/s42003-022-04206-xgoogle scholar: lookup
  35. Bailey E, Petersen JL, Kalbfleisch TS. Genetics of Thoroughbred Racehorse Performance. Annual Review of Animal Biosciences 10 (2022): 131–150.
    doi: 10.1146/annurev-animal-020420-035235google scholar: lookup
  36. Kavanagh K. First CRISPR Horses Spark Controversy: What's Next for Gene‐Edited Animals?. Nature 645 (2025): 565–566.
    doi: 10.1038/d41586-025-02800-7google scholar: lookup
  37. Iyer V, Boroviak K, Thomas M. No Unexpected CRISPR‐Cas9 Off‐Target Activity Revealed by Trio Sequencing of Gene‐Edited Mice. PLoS Genetics 14 (2018): e1007503.
    doi: 10.1371/journal.pgen.1007503google scholar: lookup
  38. Ran FA, Hsu PD, Wright J. Genome Engineering Using the CRISPR‐Cas9 System. Nature Protocols 8 (2013): 2281–2308.
    doi: 10.1038/nprot.2013.143google scholar: lookup
  39. Erbs V, Lorentz R, Eisenman B. Increased On‐Target Rate and Risk of Concatemerization After CRISPR‐Enhanced Targeting in ES Cells. Genes (Basel) 14 (2023): 401.
    doi: 10.3390/genes14020401google scholar: lookup
  40. Skryabin BV, Kummerfeld D-M, Gubar L. Pervasive Head‐to‐Tail Insertions of DNA Templates Mask Desired CRISPR‐Cas9‐Mediated Genome Editing Events. Science Advances 6 (2020): eaax2941.
    doi: 10.1126/sciadv.aax2941google scholar: lookup
  41. Hanlon KS, Kleinstiver BP, Garcia SP. High Levels of AAV Vector Integration Into CRISPR‐Induced DNA Breaks. Nature Communications 10 (2019): 4439.
    doi: 10.1038/s41467-019-12449-2google scholar: lookup
  42. Scholefield J, Harrison PT. Prime Editing—An Update on the Field. Gene Therapy 28 (2021): 396–401.
    doi: 10.1038/s41434-021-00263-9google scholar: lookup
  43. Carlson DF, Lancto CA, Zang B. Production of Hornless Dairy Cattle From Genome‐Edited Cell Lines. Nature Biotechnology 34 (2016): 479–481.
    doi: 10.1038/nbt.3560google scholar: lookup
  44. Norris AL, Lee SS, Greenlees KJ. Template Plasmid Integration in Germline Genome‐Edited Cattle. Nature Biotechnology 38 (2020): 163–164.
    doi: 10.1038/s41587-019-0394-6google scholar: lookup
  45. Lauritzen F, Solheim A. The Purpose and Effectiveness of Doping Testing in Sport. Frontiers in Sports and Active Living 6 (2024): 1386539.
    doi: 10.3389/fspor.2024.1386539google scholar: lookup
  46. Equey T, Broséus J, Baume N, Aikin R. Trends in the Detection of Erythropoietin Receptor Agonists (ERAs) in Anti‐Doping: An Analysis of Recent Adverse Analytical Findings (AAFs). Drug Testing and Analysis 17 (2025): 1254–1259.
    doi: 10.1002/dta.3828google scholar: lookup
  47. Tozaki T, Ohnuma A, Nakamura K. Detection of Indiscriminate Genetic Manipulation in Thoroughbred Racehorses by Targeted Resequencing for Gene‐Doping Control. Genes (Basel) 13 (2022): 1589.
    doi: 10.3390/genes13091589google scholar: lookup
  48. Ryder E, Harding C, Maniego J, Hincks P, Scarth J. Screening for Gene Editing Events in the Myostatin Gene by Long‐Read Sequencing. Proceedings of the 23rd International Conference of Racing Analysts and Veterinarians 2023, 24–29.
  49. Maniego J, Swinburne J, Hincks P. Evaluation of a Targeted Enrichment Panel for Gene Editing Detection and Assessment of Population Variation in Thoroughbred Horses. Animal Genetics 56 (2025): e70047.
    doi: 10.1111/age.70047google scholar: lookup
  50. Tozaki T, Ohnuma A, Takasu M. Detection of Non‐Targeted Transgenes by Whole‐Genome Resequencing for Gene‐Doping Control. Gene Therapy 28 (2021): 199–205.
    doi: 10.1038/s41434-020-00185-ygoogle scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,075 horse owners like you who receive our email updates on horse health and nutrition.